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Abstract
In mycobacteria, CycA a D-serine, L- and D-alanine, and glycine transporter also functions in the uptake of D-cycloserine, an
important second-line anti-tubercular drug. A single nucleotide polymorphism identified in the cycA gene of BCG was
hypothesized to contribute to the increased resistance of Mycobacterium bovis bacillus Calmette-Gue´rin (BCG) to D-
cycloserine compared to wild-type Mycobacterium tuberculosis or Mycobacterium bovis. Working along these lines, a
merodiploid strain of BCG expressing Mycobacterium tuberculosis CycA was generated and found to exhibit increased
susceptibility to D-cycloserine albeit not to the same extent as wild-type Mycobacterium tuberculosis or Mycobacterium bovis.
In addition, recombinant Mycobacterium smegmatis strains expressing either Mycobacterium tuberculosis or Mycobacterium
bovis CycA but not BCG CycA were rendered more susceptible to D-cycloserine. These findings support the notion that
CycA-mediated uptake in BCG is impaired as a result of a single nucleotide polymorphism; however, the partial contribution
of this impairment to D-cycloserine resistance suggests the involvement of additional genetic lesions in this phenotype.
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Introduction
Mycobacterium bovis bacillus Calmette-Gue´rin (BCG), is a live
vaccine originally derived from a virulent isolate of Mycobacterium
bovis, and has been used to immunize more than three billion
people against tuberculosis [1]. Despite widespread use, the
protective efficacy imparted by BCG wanes significantly with time,
and the molecular mechanism for this is poorly understood [1,2].
Additionally, the mechanisms underlying the derivation of
attenuated BCG from virulent M. bovis also remain incompletely
understood [1,2]. To further complicate matters, 13 strains of
BCG with documented differences in attenuation and protective
efficacy currently exist, and several of these are in use in various
parts of the world [3,4]. Clearly, the basic biology of BCG is far
from being fully understood. The availability and simultaneous
analyses of complete genome sequences of several M. bovis and
BCG strains however have generated fresh insights into the
biology of BCG [1,4–6]. Indeed, the demonstration that loss of the
RD1 locus by BCG was a key event leading to its attenuation,
originated from such comparative genome studies [7].
D-cycloserine (DCS), a cyclic analog of D-alanine, is an
important second-line antibiotic used to treat multi-drug- and
extensively drug-resistant Mycobacterium tuberculosis infections [8,9].
Compared to wild-type M. tuberculosis and M. bovis, BCG has
always been found to be more resistant to DCS [6,10]. Although
the molecular basis for this phenotype is unknown, this feature is
used to differentiate the vaccine strain from M. bovis and M.
tuberculosis strains [10]. In vitro, DCS inhibits M. tuberculosis alanine
racemase (Alr) which converts L-alanine to D-alanine, and D-
alanine:D-alanine ligase (Ddl) which synthesizes D-alanine penta-
peptides [8,11,12]. Both enzymes are required for the synthesis of
peptidoglycan in the cell wall of mycobacteria [8,11,12].
Overproduction of Alr and Ddl in BCG and Mycobacterium
smegmatis confers increased DCS resistance [13,14], while their
genetic inactivation in M. smegmatis increases susceptibility to the
drug [15,16]. The resistance determinants and the cellular targets
of DCS in M. tuberculosis and M. bovis are presumed to be Alr and
Ddl, both of which are essential in M. tuberculosis [17]. However,
the nucleotide sequences and expression patterns of alr and ddl in
M. bovis and BCG appear to be identical and as such, might not
contribute to the DCS resistance of the vaccine strain [1,6].
A non-synonymous single nucleotide polymorphism (nsSNP) in
the cycA gene of all BCG strains was recently identified and
predicted to result in a glycine 122 to serine substitution (G122S)
in the transporter [6]. CycA is a bacterial D-serine/L- and D-
alanine/glycine/D-cycloserine: proton symporter, comprising 12
helical trans-membrane domains, of the amino acid transporter
(AAT) family (TCID: 2.A.3.1.7) [18]. In the early 1970’s, David
isolated and characterised two low-level and equally DCS-resistant
forms of M. tuberculosis mutants - one that was also D-serine, L- and
D-alanine, and glycine uptake defective, and the other uptake
competent [19]. Point mutations resulting in transitions and
transversions, as well as small deletions and duplications within the
cycA gene of Escherichia coli, have been found to confer resistance to
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DCS [20]. Inspired by these reports, it was hypothesized that the
G122S change functionally impairs BCG CycA and contributes to
the vaccine strain’s characteristic resistance to DCS [6].
A bioinformatics analysis shows that the G122S change in BCG
CycA lies in a presumably critical extracellular loop between the
conserved third and fourth helical trans-membrane domains.
Taking a genetic approach we show that BCG CycA is indeed
impaired for DCS uptake, however the G122S change only
partially contributes to DCS resistance in BCG, thus implicating
additional mutations in this phenotype.
Results
In silico Analyses and Helical Trans-membrane Domain
Modeling Predicts a Functionally Important Extracellular
Loop in CycA
Comparison of CycA orthologues from six different mycobac-
teria revealed 72–99% identity at the amino acid sequence level.
Multi-species protein sequence alignment shows that CycA from
all mycobacterial strains, except BCG possess a conserved glycine
residue in position 122 (Figure 1A). Helical trans-membrane
(HTM) domain modeling of the M. bovis AF 2122/97 CycA based
on HMMTOP prediction [21], shows the transporter to be a cell
membrane protein with 12 HTM domains (Figure 1B). The
G122S change in BCG CycA is predicted to lie in an extracellular
loop between the third and fourth trans-membrane helices
(Figure 1B). Similar modeling of the HTM domains of M. tuber-
culosis H37Rv, M. marinum M and M. smegmatis mc2155 CycA also
place the conserved glycine residue at the beginning of the
extracellular loop between the third and fourth trans-membrane
helices. Single point mutations in the cycA gene have been
identified in DCS-resistant E. coli mutants [20]. Therefore E. coli
CycA was also modeled and DCS-resistance-associated single
point mutations were mapped to the model. Like the mycobac-
terial CycA proteins, E. coli CycA was predicted to form a
membrane protein with 12 HTM domains. Of twenty previously
identified point mutations, we were able to place a threonine 114
to proline substitution (from an adenine to cytosine transversion)
[20], in the extracellular loop between the third and fourth trans-
membrane helices of E. coli CycA (Figure S1).
Our in silico analyses suggest that the extracellular loop between
the third and fourth trans-membrane helices of CycA may be
sensitive to modifications and is functionally important for
transport activity.
Merodiploid Expression of M. tuberculosis CycA in BCG
Partially Restores Susceptibility to D-cycloserine
A merodiploid strain of M. bovis BCG-Pasteur was generated by
transformation with an integrating cosmid (I425) containing the
M. tuberculosis cycA allele. Sequencing from the 59-end of the cycA
PCR product amplified from the genomic DNA of a Pasteur::I425
knock-in clone showed both GGC (encoding Gly) and AGC
(encoding Ser) sequences, indicating the successful integration of
the cosmid into the chromosome (Figure 2A). In contrast, a
Pasteur::pYUB412 control showed only the AGC (encoding Ser)
sequence (Figure 2A). 39-end sequencing of cycA PCR products
from both clones confirmed these findings.
The susceptibility of the Pasteur::I425 knock-in strain to DCS
was assessed and compared to that of the Pasteur::pYUB412
control strain. In 7H9 broth cultures containing increasing
concentrations of DCS (0, 2, 4, 8, 16 and 32 mg/mL), the
Pasteur::pYUB412 strain showed complete growth inhibition at
.32 mg/mL of the antibiotic, which is consistent with published
observations [10,13,22]. The Pasteur::I425 strain however,
appeared to be more susceptible to DCS, exhibiting significant
growth inhibition at 16 and 8 mg/mL DCS compared to the
control strain – the colony forming units of the Pasteur::I425 strain
recovered was almost 1-log less at these concentrations of DCS
than that of the control strain (Figure 2B). The difference in
susceptibility to DCS between the two strains was even more
pronounced in experiments measuring growth inhibition over time
upon exposure to 32 mg/mL of the antibiotic. Pasteur::I425
showed more rapid inhibition of growth by DCS compared to the
Pasteur::pYUB412 strain as the colony forming units of the knock-
in strain recovered at all time- points post-exposure was
consistently 1-log lower than the control strain (Figure 2C).
However, we did not observe in the Pasteur::I425 strain, the
restoration of wild-type M. tuberculosis or M. bovis levels of DCS
susceptibility, which is reportedly between 4 and 5 mg/mL of DCS
[10,19].
We next wanted to verify that the higher susceptibility of the
Pasteur::I425 strain to DCS was not due to the integration of an
extra copy of the cycA gene. Although M. smegmatis mc2155 has a
higher MIC for DCS [13,14] compared to members of the
M. tuberculosis complex, we transformed this strain with I425 and
pYUB412 to test if we could obtain a similar fold increase in
susceptibility to DCS as seen with BCG. Using M. tuberculosis cycA-
specific primers we confirmed the successful integration of the
cosmid prior to testing with DCS (data not shown). Growth of
wild-type M. smegmatis mc2155 is inhibited by DCS at$75 mg/mL
[13,14], and consistent with this, theM. smegmatis::pYUB412 strain
exhibited complete growth inhibition at $80 mg/mL DCS
(Figure 2D). The growth of the M. smegmatis::I425 knock-in strain
was inhibited by DCS to the same extent as the M. smegmatis::-
pYUB412 control strain (Figure 2D). Likewise, time-course
experiments measuring growth inhibition by DCS also did not
show significant differences between the two strains (Figure 2E).
This shows that having one extra copy of M. tuberculosis cycA does
not appreciably increase DCS susceptibility in M. smegmatis. All of
these observations taken together indicate that the increased DCS
susceptibility of Pasteur::I425 results from the production of a
functional CycA in a genetic background expressing either a non-
functional or impaired CycA.
M. smegmatis Overexpressing BCG CycA does not
become More Susceptible to DCS
Heterologous expression of M. tuberculosis proteins involved in
efflux and drug resistance in M. smegmatis has been an effective
approach to study their function [23–25]. We hypothesized that if
M. bovis BCG CycA is defective, then M. smegmatis strains
overexpressing functional M. tuberculosis and M. bovis CycA but
not BCG CycA, would become more susceptible to DCS-
mediated growth inhibition. Working along these lines, M. tuber-
culosis, M. bovis and BCG cycA alleles and their promoter regions
were individually cloned into the pMD31 plasmid for multi-copy
ectopic expression in M. smegmatis mc2155. Colony PCR was used
to discriminate bona fide transformants harbouring plasmids
containing M. tuberculosis, M. bovis or BCG cycA alleles from those
harbouring the empty pMD31 vector alone (data not shown).
The DCS sensitivities of these recombinant M. smegmatis strains
were then tested in 7H9 broth containing increasing concentra-
tions of DCS (0, 40, 80 or 160 mg/mL). M. smegmatis strains
producing M. tuberculosis and M. bovis CycA exhibited significantly
increased susceptibility to DCS-mediated growth inhibition
compared to the vector-only control strain (Figure 3A). In
contrast, the susceptibility of M. smegmatis producing BCG CycA
was similar to that of the vector-only control strain (Figure 3A).
Consistent with this observation, in the presence of 200 mg/mL
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DCS, only M. smegmatis strains producing M. tuberculosis and
M. bovis CycA but not BCG CycA exhibited significantly faster
growth inhibition compared to the vector-only control (Figure 3B).
These results indicate that raising the gene-dosage of cycA readily
increases DCS susceptibility in M. smegmatis. More importantly it
shows that BCG CycA is defective because even in the
M. smegmatis genetic background, raising the gene-dosage of
BCG cycA does not affect its susceptibility to DCS.
Extra Copies of cycA Alleles in Mycobacteria do not
Confer an in vitro Growth Advantage
Since CycA is a D-serine, L- and D-alanine, and glycine
transporter, we wanted to verify that the differences in DCS
susceptibilities observed were not due to changes in the growth
rates of the strains tested. Accordingly growth measurements were
made for all of the strains in 7H9 broth. No difference in growth
between the merodiploid Pasteur::I425 and the Pasteur::pYUB412
control strain were found (data not shown). Similarly no growth
differences between M. smegmatis::I425 and M. smegmatis::pYUB412
were observed (data not shown). Consistent with the above results,
M. smegmatis strains producing M. tuberculosis, M. bovis and BCG
CycA, also grew at rates similar to the control strain in 7H9 media
(data not shown). These findings indicate that expression of extra
copies of cycA do not confer a growth advantage to the host strain
in the culture media used to test for susceptibility to DCS.
Discussion
We employed bioinformatics as well as two complementary
genetic approaches to investigate the involvement of the nsSNP in
BCG cycA in DCS resistance. Evidence is provided that suggests
this nsSNP causes a defect in the BCG CycA transporter but only
partially contributes to DCS resistance in the vaccine strain.
Figure 1. Analyses of CycA amino acid sequences. (A) Partial CycA amino acid sequence alignment of various mycobacteria (the conserved
G122 residue is indicated by the arrow). (B) 2-dimensional topological representation of M. bovis CycA with the G122S mutation found in all BCG
(circled) in the extracellular loop (boxed) between the 3rd and 4th trans-membrane helices from the amino (N) terminus.
doi:10.1371/journal.pone.0043467.g001
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Figure 2. Characterization of cycAmerodiploid BCG andM. smegmatis strains. (A) Sequence of the SNP containing region in cycA from BCG-
Pasteur::I425 and BCG-Pasteur::pYUB412 clones from the 59 end. (B) CFUs of BCG-Pasteur::I425 (white bars) and BCG-Pasteur::pYUB412 (black bars) 4
days after treatment with indicated concentrations of DCS. (C) CFUs of BCG::I425 (solid squares) and BCG::pYUB412 (solid diamonds) obtained over
time upon exposure to 32 mg/mL DCS. (D) CFUs of M. smegmatis::I425 (white bars) and M. smegmatis::pYUB412 (black bars) 24 hours after treatment
with indicated concentrations of DCS. (E) CFUs of M. smegmatis::I425 (solid squares) and M. smegmatis::pYUB412 (solid diamonds) obtained over time
upon exposure to 200 mg/mL DCS. Data points and error bars are means 6 standard deviations. Statistically significant differences are denoted by
asterisks (*, P,0.05; **, P,0.01). Representative of 3 independent experiments performed in duplicate.
doi:10.1371/journal.pone.0043467.g002
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Trans-membrane helical domain modeling places the BCG
G122S mutation in an extracellular loop between the conserved
third and fourth helical trans-membrane domains of CycA. This
finding hints at possible substrate recognition or binding defects at
the structural level in BCG CycA and warrants further study.
Consistent with the notion that BCG CycA is defective for DCS
uptake, heterologous overexpression of CycA from M. tuberculosis
and M. bovis but not from BCG in M. smegmatis results in increased
susceptibility to DCS. This effect of increased cycA gene-dosage on
DCS susceptibility in M. smegmatis raises the question of whether a
decrease in CycA expression in BCG might result in increased
resistance. However, the identical expression patterns of cycA in
M. bovis and BCG rule out this possibility [1,6]. More importantly,
the G122S mutation in BCG CycA appears to be a minor
contributor as we were unable to restore M. tuberculosis and
M. bovis levels of DCS susceptibility to the merodiploid Pas-
teur::I425 strain. This is not surprising as the isolation of two
equally DCS-resistant mutants of M. tuberculosis, one of which is
transport defective and the other transport competent, has been
reported [19]. This strongly suggests there are other genetic lesions
besides the nsSNP in cycA that also contribute to DCS resistance in
BCG. Indeed an M. smegmatis isolate, resistant to both DCS and
vancomycin was found to have no mutations in the alr, ddl or cycA
genes [26]. Only multi-copy transformation of a gene encoding a
putative penicillin-binding protein (Pbp4) homolog restored DCS
and vancomycin susceptibility to this strain [26]. Our analyses of
pbp genes in BCG however did not reveal any nsSNPs that might
explain the BCG phenotype. Moreover, a recent metabolomic
study of M. smegmatis revealed that there may potentially be
alternative routes to D-alanine synthesis in mycobacteria that
could circumvent DCS inactivation of Alr and Ddl [12]. This
notion is supported by the observation that alr mutants of
M. smegmatis are not complete D-alanine auxotrophs [12,16]. As
such, genetic mutations in these alternate alanine metabolic
pathways could potentially augment CycA-mediated DCS resis-
tance in BCG.
BCG underwent in vitro evolution during its initial derivation
from a virulent M. bovis progenitor strain as well as during its
subsequent global dissemination [1,2]. A consequence of this
evolution was the acquisition of mutations causing defects in L-
serine and L-alanine catabolism, dysregulated nitrogen metabolic
pathways and in vitro growth defects [27]. CycA is the sole
transporter for D-serine, L- and D-alanine, and glycine in
mycobacteria, and their uptake by the transporter is induced by
L-alanine [19]. Although in this study BCG and M. smegmatis
strains bearing extra cycA alleles and their control strains grew
similarly in 7H9 broth, growth differences may yet appear in L-
serine and/or L-alanine-replete conditions not found in 7H9
broth. A link between defective L-serine and L-alanine catabolism
and the acquisition of the CycA G122S mutation impairing D-
serine, L- and D-alanine and DCS uptake is intriguing and merits
additional investigation as this will add to our understanding of
BCG nitrogen metabolism.
In conclusion, this study reveals the involvement of CycA in the
resistance of BCG to DCS and provides fresh insights into BCG
biology as well as clues for the improvement of DCS as an anti-
mycobacterial agent.
Materials and Methods
Reagents
Restriction and DNA modifying enzymes were purchased from
New England Biolabs (Ipswich, MA, USA). High fidelity Pfu
polymerase for PCR was purchased from Promega (Madison, WI,
USA). Custom oligonucleotides were synthesized by Microsynth
(Balgach, Switzerland). Middlebrook 7H9, 7H11 media, albumin-
dextrose-catalase (ADC) and oleic acid-albumin-dextrose-catalase
(OADC) were purchased from Becton-Dickinson (Franklin Lakes,
NJ, USA). All other chemicals and reagents were purchased from
Sigma-Aldrich (St. Louis, MO, USA).
Figure 3. Susceptibilities of M. smegmatis strains overexpressing cycA alleles to DCS. (A) CFUs of recombinant M. smegmatis strains after
24 hours of treatment with indicated concentrations of DCS. (C) CFUs of recombinant M. smegmatis strains obtained over time upon exposure
200 mg/mL DCS. M. smegmatis harbouring pMD31 (black bars), pMDcycAMtb (white bars), pMDcycAMbov (light-gray bars) and pMDcycABCG (dark-gray
bars). Data points and error bars are means 6 standard deviations. Statistically significant differences are denoted by asterisks (*, P,0.05).
Representative of three independent experiments performed in duplicate.
doi:10.1371/journal.pone.0043467.g003
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Bacterial Strains and Growth Conditions
M. tuberculosis H37Rv, M. bovis BCG Pasteur 1173P2 and
M. smegmatis mc2155 were routinely cultured in 7H9 broth
supplemented with ADC and 0.05% Tween-80 or on 7H11 agar
plates supplemented with OADC. For the selection of relevant
mycobacterial clones, hygromycin at 50 mg/mL and kanamycin at
25 mg/mL were used.
Genetic Manipulations and Genotyping
An integrating cosmid (I425) [28], bearing theM. tuberculosis cycA
allele (rv1704c) was transformed into M. bovis BCG-Pasteur 1173P2
and M. smegmatis mc2155 following standard electroporation pro-
cedures [29]. pYUB412, the cosmid backbone, was electroporated
to obtain parental control strains. Genomic DNA was extracted
from severalM. bovisBCGcolonies obtained after selection on 7H11
agar plates containing hygromycin. Positive BCG-Pasteur::I425
clones were verified by PCR amplification of the genomic DNA
using cycA-specific internal primers (cycA-int-Forward: agctgctgctgtc-
gaacctg and cycA-int-Reverse: gttgggaagaacccgttgtc) and sequencing
of the PCR products. M. smegmatis::I425 clones were obtained and
identified by PCR amplification using M. tuberculosis cycA-specific
primers described above.M. smegmatis::pYUB412 served as control.
Table 1 describes all strains generated in this study.
Plasmid Constructions, Generation and Identification of
Recombinant M. smegmatis Strains Over-expressing
M. tuberculosis, M. bovis and BCG CycA
Multi-copy episomal vectors containing cycA alleles fromM. tuber-
culosis, M. bovis and M. bovis BCG were constructed as follows: cycA
gene including 267 bp upstream of the start site was amplified from
M. tuberculosis H37Rv, M. bovis AF2122/97 and M. bovis BCG-
Pasteur1173P2genomicDNAusinghigh fidelityPfupolymeraseand
primers cycA-HindIII-Forward: cagaagcttatcggtgccgcccaact and
cycA-PstI-Reverse: cgcctgcagcgtgggcgaggacatag introducing 59-
HindIII (bold italics) and 39-PstI (bold italics) restriction sites. The
PCRfragmentsobtainedweredigestedwithHindIIIandPstI,purified
and then ligated into HindIII- and PstI- linearized pMD31 [30].
Plasmid clones containing cycA alleles were verified by sequencing
before electroporation into M. smegmatis mc2155. Positive transfor-
mantswere identifiedbycolonyPCRusing theprimers cycA-HindIII-
Forward and cycA-PstI-Reverse described above.
D-cycloserine Susceptibility Testing
DCS is unstable in aqueous solutions buffered at pH 7 including
Middlebrook 7H9 broth [8,31] therefore working solutions of the
antibiotic were prepared freshly in sodium phosphate buffer
(pH 9.0) just before use. Two-fold serial dilutions of DCS covering
the required range of concentrations were prepared in 7H9 broth
(supplementedwithADCand 0.05%Tween-80) for all experiments.
For assessing DCS-sensitivity over time, the antibiotic was added to
7H9 broth (supplemented with ADC and 0.05% Tween-80) at
approximately 2X the reported MIC per strain for every experi-
ment. Colony forming units at different time points were determined
by 7H11 agar plate spreading of serially diluted aliquots of cells.
Statistics
The unpaired, two-tailed t test was used to assess the statistical
significance in differences when comparing experimental groups
using the GraphPad Prism program (http://www.graphpad.com).
CycA Amino Acid Sequence Analyses and Helical Trans-
membrane Domain Modeling
Alignments of CycA amino acid sequences of different
mycobacteria obtained from TubercuList, MarinoList and
SmegmaList genome browsers (http://mycobrowser.epfl.ch/)
[32] were done using the MultAlin server (http://multalin.
Table 1. DNA and bacterial strains used in this work.
Plasmid/Cosmid Description Reference
pMD31 Episomal, multicopy, KanR, oriE, oriM [30]
pMDcycAMtb Episomal, multicopy, M. tb cycA, Kan
R, oriE, oriM This study
pMDcycAMbov Episomal, multicopy, M. bovis cycA, Kan
R, oriE, oriM This study
pMDcycABCG Episomal, multicopy, BCG cycA, Kan
R, oriE, oriM This study
pYUB412 attB site integrative cosmid backbone, HygR, AmpR, oriE [28]
I425 attB site integrative cosmid with rv1701 to rv1733c fragment, HygR, AmpR, oriE [28]
Strains Description Reference
M. tb H37Rv Wild-type [36]
M. smegmatis mc2155 Wild-type [28]
M. bovis BCG-Pasteur 1173P2 Vaccine strain [1]
Pasteur::pYUB412 BCG-Pasteur::pYUB412, HygR This study
Pasteur::I425 BCG-Pasteur::I425, HygR This study
mc2155::pYUB412 M. smegmatis mc2155::pYUB412, HygR This study
mc2155::I425 M. smegmatis mc2155::I425, HygR This study
mc2155/pMD31 M. smegmatis mc2155+ pMD31, KanR This study
mc2155/pMDcycAMtb M. smegmatis mc
2155+ pMDcycAMtb, KanR This study
mc2155/pMDcycAMbov M. smegmatis mc
2155+ pMDcycAMbov, KanR This study
mc2155/pMDcycABCG M. smegmatis mc
2155+ pMDcycABCG, KanR This study
doi:10.1371/journal.pone.0043467.t001
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toulouse.inra.fr/multalin/multalin.html) [33]. Secondary structure
prediction was done using the PSIPRED protein structure
prediction server (http://bioinf.cs.ucl.ac.uk/psipred/) [34]. Pre-
diction of trans-membrane domains in CycA amino acid
sequences was done using the HMMTOP (version 2) algorithm
[21]. Two-dimensional graphical representations of the trans-
membrane topologies of CycA sequences were made using the
TMRPres2D program (http://bioinformatics.biol.uoa.gr/
TMRPres2D/index.jsp) [35].
Supporting Information
Figure S1 2-dimensional topological representation of
E. coli CycA with a DCS-resistance associated T114P
mutation (circled) in the extracellular loop (boxed)
between the 3rd and 4th trans-membrane helices from
the amino terminus.
(TIF)
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